相关实验视频
Updated: Jul 25, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
工程蛋白和Jakinib纳米平台与非凡的类风湿性关节炎治疗
Yuanxin Li1,2, Bo Li3, Gang Wang4
1State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022 China.
Nano research
|June 26, 2023
概括
这项研究引入了新型纳米载体的upadacitinib,显著改善了类风湿性关节炎 (RA) 治疗. 该纳米疗法提供了增强的疗效,减少了副作用,并使实时成像能够更好地监测RA治疗.
科学领域:
- 生物技术是生物技术.
- 纳米医学是一种纳米医学.
- 类风湿病学 类风湿病学
背景情况:
- 类风湿性关节炎 (RA) 是一种常见的炎症性关节疾病,导致残疾.
- 简氏激酶抑制剂 (Jakinibs) 是有效的 RA 治疗方法,但需要频繁剂量并引起毒性.
- 目前的RA疗法面临的挑战是剂量频率和严重的副作用.
研究的目的:
- 开发一种新型的纳米载体系统,用于控制性释放upadacitinib.
- 为了提高阿帕达西丁的疗效和安全性,治疗RA.
- 为了实现非侵入性成像,以实时监测RA治疗.
主要方法:
- 开发使用重组化学蛋白来输送upadacitinib的纳米载体.
- 在老鼠模型中的体内评估,以评估治疗疗效和药理动力学.
- 将光蛋白纳入RA病变的非侵入性成像.
主要成果:
- 该纳米载体系统证明了阿帕达西提尼布的受控释放,其超长半衰期为45小时.
- 与免费的upadacitinib相比,达到4倍以上的生物可用性,将剂量间隔延长到2周.
- 显著减轻过度免疫抑制和减少白细胞水平等副作用,同时提高治疗疗效.
结论:
- 开发的纳米治疗系统为RA治疗提供了卓越的疗效,安全性和视觉监测.
- 这种纳米平台延长了剂量间隔,并减少了与Jakinibs相关的毒性.
- 该战略为设计用于各种治疗应用的纳米药物提供了一个多功能平台.
相关概念视频
01:20The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
177
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
177
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
201
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
201
01:16TGF - β Signaling Pathway
7.5K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.5K
01:21Rheumatic Heart Disease III: Medical Management
22
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
22